$12.6M
Qualified
maximum offering price, as qualified
—
Reported Sold
no 1-K or 1-Z states a sold amount
3
Filings
across 1 offering
Equity Classes
| Type | Class | Outstanding | CUSIP | Publicly Traded |
|---|---|---|---|---|
| common | Common Stock | 699,991,000 | 989574108 | Over-the-Counter |
| debt | Debt Securities | 0 | — | — |
| preferred | Series A-1 Preferred Stock | 3,000,000 | — | — |
Service Providers
| Role | Provider |
|---|---|
| auditor | None |
| blue sky | Jackson L. Morris |
| finder | None |
| legal | Jackson L. Morris |
| promoter | None |
| sales commission | None |
| underwriter | None |
Offerings
| File Number | Filings | First Filed | Last Filed | Price/Security | Securities Offered | Outstanding | Aggregate Offering | Estimated Net | Withdrawn |
|---|---|---|---|---|---|---|---|---|---|
| 024-11172 | 3 | 2020-03-05 | 2020-07-10 | $0.18 | 70,000,000 | 699,991,000 | $12.6M | $0 | 2020-11-06 |
The statements and reported figures behind Zimmerman BioPharma Holding, Inc.
Operations, the balance sheet and cash flows as filed, year by year — the filer's own captions, not a mapped chart of accounts — plus the tagged figures from every Form 1-A family filing, plotted on the dates they were actually reported. EDGAR still has each 1-K; the dashboard lays every year they filed next to it.
- Every caption as the filer wrote it, across every annual report — not just the latest 1-K
- Tagged reported figures across every filing — revenue, assets, cash — with a sparkline on the actual filing dates
- A sparkline on each annual-statement line, so the shape is visible before the figures
- A revenue series dated to the filings that reported it
- A filing history that says what each document contributed, not only that it exists
- Follow it, and see it change on your watchlist
External link: SEC Filings